Olivier Rixe

15.1k total citations · 2 hit papers
205 papers, 11.3k citations indexed

About

Olivier Rixe is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Olivier Rixe has authored 205 papers receiving a total of 11.3k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Oncology, 81 papers in Pulmonary and Respiratory Medicine and 68 papers in Molecular Biology. Recurrent topics in Olivier Rixe's work include Renal cell carcinoma treatment (34 papers), Cancer Treatment and Pharmacology (32 papers) and Lung Cancer Treatments and Mutations (24 papers). Olivier Rixe is often cited by papers focused on Renal cell carcinoma treatment (34 papers), Cancer Treatment and Pharmacology (32 papers) and Lung Cancer Treatments and Mutations (24 papers). Olivier Rixe collaborates with scholars based in France, United States and Spain. Olivier Rixe's co-authors include Stéphane Oudard, Robert J. Motzer, Ronald M. Bukowski, M. Dror Michaelson, Paul Bycott, Robert A. Figlin, Thomas E. Hutson, Piotr Tomczak, Charles M. Baum and Sylvie Négrier and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Olivier Rixe

193 papers receiving 11.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

2007 4.5k citations Robert J. Motzer, Thomas E. Hutson et al. New England Journal of Medicine profile →
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel

1996 510 citations Olivier Rixe et al. profile →

Peers

Countries citing papers authored by Olivier Rixe

Since Specialization

Citations

This map shows the geographic impact of Olivier Rixe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olivier Rixe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olivier Rixe more than expected).

Fields of papers citing papers by Olivier Rixe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olivier Rixe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olivier Rixe. The network helps show where Olivier Rixe may publish in the future.

Co-authorship network of co-authors of Olivier Rixe

This figure shows the co-authorship network connecting the top 25 collaborators of Olivier Rixe. A scholar is included among the top collaborators of Olivier Rixe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olivier Rixe. Olivier Rixe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First‐in‐human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors 2025 ·Cancer ·Timothy A. Yap, Olivier Rixe, Capucine Baldini, Ursa Brown‐Glaberman, (unknown), David S. Hong, Christophe Massard, Jameel Muzaffar, Andreea Varga, Emrullah Yilmaz, (unknown), (unknown), Yi Liu, Matthew Hruska, Henry Zhao, (unknown), Solmaz Sahebjam	2
2	A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas 2024 ·Clinical Cancer Research ·Olivier Rixe, John L. Villano, Robert Wesolowski, Anne M. Noonan, Vinay K. Puduvalli, Trisha M. Wise‐Draper, Richard Curry, Emrullah Yilmaz, (unknown), Besim Öğretmen, (unknown), (unknown)	1
3	Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors 2022 ·Clinical Cancer Research ·Diwakar Davar, Roberta Zappasodi, Hong Wang, Girish S. Naik, Takami Sato, Todd M. Bauer, David L. Bajor, Olivier Rixe, Walter Newman, Jingjing Qi, (unknown), Phillip Wong, (unknown), (unknown), Cynthia A. Sirard, Taha Merghoub, Jedd D. Wolchok, Jason J. Luke	37
4	A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma 2020 ·Investigational New Drugs ·David A. Reardon, Annick Desjardins, Olivier Rixe, Timothy F. Cloughesy, Shilpa Alekar, Jason H. Williams, Ray Li, Carrie Turich Taylor, Andrew B. Lassman	46
5	A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies 2017 ·Targeted Oncology ·Trisha M. Wise‐Draper, Ganesh Moorthy, Mohamad A. Salkeni, Nagla Abdel Karim, Hala Elnakat Thomas, Carol A. Mercer, Muhammad S. Beg, (unknown), Olugbenga Olowokure, Hassana Fathallah, Sara C. Kozma, George Thomas, Olivier Rixe, Pankaj B. Desai, John C. Morris	95
6	Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma 2015 ·Expert Opinion on Drug Discovery ·Yousef Zakharia, (unknown), Olivier Rixe	9
7	Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma 2011 ·Clinical Cancer Research ·John P. Fruehauf, Jose Lutzky, David H. McDermott, Charles K. Brown, Jean‐Baptiste Méric, Brad Rosbrook, David R. Shalinsky, Katherine Liau, Andreas G. Niethammer, Sinil Kim, Olivier Rixe	93
8	A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings 2010 ·Cancer Immunology Immunotherapy ·Stéphane Oudard, Olivier Rixe, Benoit Beuselinck, Claude Linassier, Eugéniu Banu, Jean-Pascal Machiels, Marion Baudard, François Ringeisen, Thierry Velu, Marie‐Aude Lefrère‐Belda, Jean‐Marc Limacher, Wolf H. Fridman, Michel Azizi, Bruce Acres, Éric Tartour	71
9	A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer 2009 ·Cancer Chemotherapy and Pharmacology ·Olivier Rixe, Sandra Franco, Denise A. Yardley, Stephen Johnston, Miguel Martín, Banu Arun, Stephen P. Letrent, Hope S. Rugo	43
10	Tumeur épithéliale primitive de la tête de l’épididyme 2008 ·Progrès en Urologie ·(unknown), S. Bart, Olivier Rixe, E. Compérat, (unknown), E. Chartier-Kästler, (unknown)	0
11	Place de l’imagerie par Tomographie par Émission de Positons pour les tumeurs stromales gastro-intestinales 2007 ·Gastroentérologie Clinique et Biologique ·Jean‐Louis Alberini, (unknown), Myriam Wartski, É. Gontier, F. Cvitkovic, Olivier Rixe, Philippe Rougier, (unknown)	18
12	Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma breakdown → 2007 ·New England Journal of Medicine ·Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Olivier Rixe, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Sindy T. Kim, Isan Chen, Paul Bycott, Charles M. Baum, Robert A. Figlin	4471
13	Cyclooxygenase-2 as a target for anticancer drug development 2006 ·Critical Reviews in Oncology/Hematology ·(unknown), Sylvie Rottey, Ken A. Olaussen, Jean‐Charles Soria, David Khayat, Olivier Rixe, Jean-Philippe Spano	172
14	L’inhibition du protéasome : une nouvelle approche thérapeutique en onco-hématologie 2005 ·Bulletin du Cancer ·Jean‐Philippe Spano, Jacques‐Olivier Bay, Jean‐Yves Blay, Olivier Rixe	5
15	Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients 2004 ·Annals of Oncology ·L. Cals, Olivier Rixe, Éric François, R. Favre, (unknown), G. Deplanque, Abderrahmane Laadem, (unknown), Jean-Marc Béréder, David Bernardini, Patrice Herait	23
16	Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model 2004 ·Anti-Cancer Drugs ·Radan Džodić, Gonzalo Gomez-Abuin, Philippe Rougier, M. Bonnay, P Ardouin, Alain Gouyette, Olivier Rixe, Michel Ducreux, Jean‐Nicolas Munck	70
17	Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma 2003 ·Annals of Oncology ·Éric Raymond, Michel Fabbro, Valérie Boige, Olivier Rixe, Marc Frénay, Gilles Vassal, Sandrine Faivre, (unknown), Caroline Germa, (unknown), Laurent Vernillet, Jean‐Pierre Armand	67
18	Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study 2002 ·Annals of Oncology ·I. Monnet, Hubert de Crémoux, P Soulié, (unknown), (unknown), (unknown), Étienne Brain, Olivier Rixe, Y. Yataghene, J. L. Misset, Esteban Cvitkovic	31
19	Télomères, télomérase et cancer 1997 ·Bulletin du Cancer ·Jean‐Charles Soria, Olivier Rixe	0
20	Complete remission seven years after treatment for metastatic malignant melanoma 1996 ·Cancer ·Thierry Petit, Christian Borel, Olivier Rixe, Marie‐Françoise Avril, Alain Monnier, B. Giroux, Marise Weil, David Khayat	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact